<DOC>
	<DOCNO>NCT01834066</DOCNO>
	<brief_summary>This Study single arm , single centre trial check safety efficacy Bone Marrow derive autologous cell ( 100 million per dose ) patient Duchenne Muscular Dystrophy .</brief_summary>
	<brief_title>Study Safety Efficacy Bone Marrow Derived Autologous Cells Treatment Muscular Dystrophy .</brief_title>
	<detailed_description>Muscular dystrophy group inherit disorder involve muscle weakness loss muscle tissue , get bad time . Duchenne muscular dystrophy cause defective gene dystrophin ( protein muscle ) . However , often occur people without know family history condition . slowly progress diseases.it cause Muscle weakness , Difficulty motor skill , Progressive difficulty walking.Breathing difficulty heart disease , Frequent fall , weak limb , lose motor Function.Begins legs pelvis , also occur less severely arm , neck , area body.Trouble get lie position climb stair .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Patient Diagnose Duchenne Muscular Dystrophy . Aged 6 25 Years . Willingness undergo Bone Marrow derive Autologous cell Therapy . Ability comprehend explain protocol thereafter give informed consent well sign require Informed Consent form ( ICF ) study . Ability willingness regular visit hospital protocol procedure follow Patient Diagnose Duchenne Muscular Dystrophy . Patient History Immunodeficiency HIV+ , Hepatitis B , HBV TPPA+ , Tumor Markers+ History Life threaten allergic immune Mediated Reaction . site bone marrow aspiration potentially limiting Procedure . Alcohol drug abuse / dependence . Patients History Hypertension Hypersensitive .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>muscular Dystrophy stem cell</keyword>
</DOC>